Resolved hepatitis B infection in patients receiving immunosuppressive therapy: Monitor versus prophylaxis against viral reactivation

Risk of hepatitis B virus reactivation (HBVr) in patients with resolved HBV infection receiving immunosuppressive therapy has been a growing concern, particularly in the era of biological and targeted therapies. HBV monitoring versus antiviral prophylaxis against HBVr in those patients remains contr...

Descripción completa

Detalles Bibliográficos
Autores principales: Elsebaey, Mohamed A., Elbedewy, Tamer A., Elashry, Heba, Elrefaey, Waleed, Elshweikh, Samah A., Elhadidy, Ahmed A., Shalaby, Neveen A., Elsokkary, Assem Mohamed, Elashtokhy, Hossam Eldin A., Abo-Amer, Yousry Esam-Eldin, Abo-Elfetoh, Ashraf Rafat, Hassanien, Sharaf Elsayed Ali, Fouad, Amina, Abdellatif, Raghda Samir, Ismail, Amro Abdelaziz Mohammed
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2022
Materias:
4500
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9704936/
https://www.ncbi.nlm.nih.gov/pubmed/36451458
http://dx.doi.org/10.1097/MD.0000000000031962

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9704936/
https://www.ncbi.nlm.nih.gov/pubmed/36451458
http://dx.doi.org/10.1097/MD.0000000000031962

Ejemplares similares